Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 7/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15483302 | 0.96 | ALDH1A1 (0.55) | FAAHALDH1A1NAAAATMACHE | |
| SCHEMBL10775601 | 0.94 | FAAH (0.66) | FAAHALDH1A1NAAAACHEDGKA | |
| SCHEMBL28856627 | 0.92 | FAAH (0.69) | FAAHALDH1A1NAAAACHEDGKA | |
| SCHEMBL10780862 | 0.92 | FAAH (0.69) | FAAHALDH1A1NAAAACHEDGKA | |
| SCHEMBL10778909 | 0.92 | FAAH (0.69) | FAAHALDH1A1NAAAACHEDGKA | |
| SCHEMBL55229 | 0.92 | FAAH (0.69) | FAAHALDH1A1NAAAACHEDGKA | |
| SCHEMBL10778040 | 0.92 | FAAH (0.69) | FAAHALDH1A1NAAAACHEDGKA | |
| SCHEMBL4640687 | 0.88 | FAAH (0.47) | FAAHALDH1A1NAAAACHEDGKA | |
| SCHEMBL1010990 | 0.87 | FAAH (0.66) | FAAHALDH1A1NAAAATMACHE | |
| SCHEMBL29467312 | 0.83 | FAAH (0.61) | FAAHALDH1A1NAAAATMACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107876092-B | Application of titanium catalyst with cyclic structure as reaction catalyst for synthesizing benzyl carbonate or diphenyl carbonate by ester exchange | 华东理工大学 | 2023-01-10 | — | — | CN | claimed |
| CN-105061338-A | 3-methyl-quinoxaline-2-carboxylic acid chemical synthesis method based on ionic liquid system | PINGYUAN WEIFENG YONGZHU TECHNOLOGY CO LTD | 2015-11-18 | — | — | CN | claimed |
| US-12577373-B2 | Carbodiimide composition, curing agent composition, coating composition and resin cured product | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2026-03-17 | — | — | US | disclosed |
| US-20230135772-A1 | CARBODIIMIDE COMPOSITION, CURING AGENT COMPOSITION, COATING COMPOSITION AND RESIN CURED PRODUCT | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-05-04 | — | — | US | disclosed |
| EP-4130154-A1 | CARBODIIMIDE COMPOSITION, HARDENER COMPOSITION, COATING COMPOSITION, AND CURED RESIN OBJECT | Asahi Kasei Kabushiki Kaisha (JP) | 2023-02-08 | — | — | EP | disclosed |
| CN-107417719-B | Application of titanium chelate as reaction catalyst for synthesizing benzyl carbonate or diphenyl carbonate by ester exchange | 华东理工大学 | 2022-11-25 | — | — | CN | disclosed |
| CN-115190901-A | Carbodiimide composition, curing agent composition, coating composition, and resin cured product | 旭化成株式会社 | 2022-10-14 | — | — | CN | disclosed |
| CN-109053479-B | Method for synthesizing quaternary amine inner salt | 兆科药业（合肥）有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-105061338-A | 3-methyl-quinoxaline-2-carboxylic acid chemical synthesis method based on ionic liquid system | PINGYUAN WEIFENG YONGZHU TECHNOLOGY CO LTD | 2015-11-18 | — | — | CN | disclosed |
| CN-1874989-B | process for preparing -or (R) -4-halo-3-hydroxybutyric acid esters | LONZA AG | 2011-06-29 | — | — | CN | disclosed |
| CN-1874989-A | Process for preparing -or (R) -4-halo-3-hydroxybutyric acid esters | LONZA AG (CH) | 2006-12-06 | — | — | CN | disclosed |
| EP-0573184-B1 | t-Butyl (R)-(-)-4-Cyano-3-hydroxybutyrate and process for its preparation | TAKASAGO PERFUMERY CO LTD (JP) | 1996-03-13 | — | — | EP | disclosed |
| US-5430171-A | T-butyl (R)-(-)-4-cyano-3-hydroxybutyrate and process for preparing the same | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1995-07-04 | — | — | US | disclosed |
| EP-0573184-A1 | t-Butyl (R)-(-)-4-Cyano-3-hydroxybutyrate and process for its preparation | Takasago International Corporation (JP) | 1993-12-08 | — | — | EP | disclosed |
| EP-0339764-B1 | PROCESS FOR PREPARING CARNITINE | Takasago International Corporation (JP) | 1992-06-24 | — | — | EP | disclosed |
| US-4895979-A | HYDROGENATION OF GAMMA-HALO-BETA-KETO ESTER, RUTHENIUM-OPTICALLY ACTIVE PHOSPHINE CATALYST, QUATERNIZATION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1990-01-23 | — | — | US | disclosed |
| EP-0339764-A1 | Process for preparing carnitine | Takasago International Corporation (JP) | 1989-11-02 | — | — | EP | disclosed |
| US-4564696-A | Process for the production of 4-alkoxyacetoacetic acid esters | LONZA LTD. (CH) | 1986-01-14 | — | — | US | disclosed |
| US-4421922-A | Process for the production of tetronic acid | LONZA LTD. (CH) | 1983-12-20 | — | — | US | disclosed |
| US-4039570-A | DISPERSING AGENTS | LONZA LTD. (CH) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577373-B2 | Carbodiimide composition, curing agent composition, coating composition and resin cured product | CD38, PARP9, MCCC2 | FAAH 1434/4885ALDH1A1 737/4885NAAA 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.